Pioneering multispecific nanobody-based biologics to conquer disease complexity and transform patient outcomes — starting with osimertinib-resistant non-small cell lung cancer.
An integrated platform that compresses the multispecific biologics workflow — from proteomic discovery, through epitope-first engineering, into an expanded set of clinical modalities.
Serum-matured nanobody discovery from native disease proteomes, paired with ML-driven candidate triage — a 1012–1015 repertoire ranked for clinical developability before nomination.
We pick the epitope before the molecule. Multi-paratopic constructs reach cryptic and low-abundance sites, with affinity tuned from fM through nM and humanization built in.
One platform, many modalities. Modular VHH formats compose into degrader-drug-conjugates, T-cell engagers, antibody-oligos, and brain-shuttle biologics — with manufacturing built for stability and yield.
Serum-matured repertoires sampled directly from the camelid, fractionated through high-resolution mass spectrometry, and ranked into developable multi-paratopic candidates.
Model. Compare. Optimize.
Native proteomes scored by an ML model — top-ranked epitopes surfaced before chemistry begins.
Candidate format, modeled at full structure with payload geometry.
Linker chemistry and domain arrangement scored head-to-head — winning configuration auto-selected.
Top candidates passed through a five-axis developability filter — only manufacturable, low-risk molecules survive.
| Program | Modality | Indication | Discovery | Preclinical | IND-enabling | Phase 1 | Status |
|---|---|---|---|---|---|---|---|
| VT-001 | Tri-specific degrader-drug conjugate (DDC) | NSCLC & solid tumors | IND-enabling | ||||
| VT-002 | Tri-specific dual-degrader-conjugate | NSCLC & solid tumors | Preclinical | ||||
| VT-003 | Broad-tissue SdAb | CNS & Muscle | Discovery |
Open to BD conversations, scientific collaborations, and exceptional talent across protein engineering, computational discovery, and translational oncology.
